Provided are therapies, including standalone and combination therapies, for treating neuropilin-2 (NRP2)-associated diseases and conditions, which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide.L'invention concerne des thérapies, notamment des thérapies autonomes et combinées, de traitement de maladies et d'états associés à la neuropiline-2 (NRP2), qui comprennent l'utilisation d'au moins un polypeptide histidyl-ARNt synthétase (HRS).